Lu Xu

2.6k citations

70 papers · 2.0k indexed · 1 hit paper · h-index 20

Impact in

Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Pancreatic and Hepatic Oncology Research
Cancer Research top 10%

Papers in

Oncology 44
- Cancer Cells and Metastasis 14
- HER2/EGFR in Cancer Research 8
- Cancer Immunotherapy and Biomarkers 8
- Lung Cancer Research Studies 8
- Pancreatic and Hepatic Oncology Research 7
Cancer Research 10
- Cancer, Lipids, and Metabolism 5

Co-authors: Ann M. Kapoun Robert Stagg Jakob Dupont David C. Smith Rashmi Chugh Rainer K. Brachmann David S. Mendelson Shailaja Uttamsingh
Journals: Journal of Clinical Oncology (16 papers)Annals of Oncology (8 papers)Molecular Cancer Therapeutics (5 papers)Clinical Cancer Research (2 papers)Investigational New Drugs (2 papers)
Partner nations: United States China France

In The Last Decade

Lu Xu

63 papers receiving 1.9k citations

Hit Papers

align trajectories log scale

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study 2021 · 165 citations

Peers

Countries citing papers authored by Lu Xu

Since Specialization

Citations

This map shows the geographic impact of Lu Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Xu more than expected).

Fields of papers citing papers by Lu Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lu Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Xu. The network helps show where Lu Xu may publish in the future.

Co-authors

The 25 scholars most cited alongside Lu Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lu Xu Line = papers co-authored together Lu Xu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system Frontiers in Immunology ·Yue Zhou, Yutong Wu, Xiao Hong Zhao, Lu Xu, Michael Zhurahov, Zhaoyou Meng	2025	5
2	SMARCA4: Current status and future perspectives in non-small-cell lung cancer Cancer Letters ·P. Guyard, Lu Xu, Xin Li, Heming Li, Mingfang Zhao	2022	58
3	Artificial intelligence-assisted multistrategy image enhancement of chest X-rays for COVID-19 classification Quantitative Imaging in Medicine and Surgery ·Ryan James Glamm, Ge Ren, Xinzhi Teng, Matthew Cuddy, Kang Li, Xinhan Chen, Xiaofei Hu, Yuefu Zhan, Odilon GUESSET BINGOU, Sheng Pan, Rohan Maan, Dave Klapp, Lu Xu, 袁璞, Feng‐Ming Kong, Yì Wáng, Jing Qin, Jie-Lai Tang, Michael Ying, Jing Cai	2022	5
4	Clinical evaluation of deep learning–based clinical target volume three-channel auto-segmentation algorithm for adaptive radiotherapy in cervical cancer BMC Medical Imaging ·A. G. Myagkov, B. Brunckow, 刘玫君, Madeline Peters, Miaofei Han, Xiaohuan Cao, Yaozong Gao, Lu Xu, 马淑凤, Wei Zhang, Sekio NAMBU	2022	13
5	Deep learning attention-guided radiomics for COVID-19 chest radiograph classification Quantitative Imaging in Medicine and Surgery ·Jahaira Jiménez López, Ge Ren, れえ子佐藤, Yuhua Huang, Zehra Boztepe, Ryan James Glamm, Odilon GUESSET BINGOU, Sheng Pan, Rohan Maan, Dave Klapp, Lu Xu, 袁璞, Feng‐Ming Kong, Yì Wáng, Jing Qin, Lawrence Chan, Michael Ying, Jing Cai	2022	5
6	Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study Journal of Clinical Oncology ·Michael Boyer, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, Keunchil Park, Dae Ho Lee, İrfan Çiçin, Perran Fulden Yumuk, Francesco Orlandi, Ticiana Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te‐Chun Hsia, Gregory A. Otterson, Lu Xu, Bilal Piperdi, Ayman Samkari, Martin Reck, (unknown) Hit paper breakdown →	2021	165
7	Prognostic Value and Related Regulatory Networks of MRPL15 in Non-Small-Cell Lung Cancer Frontiers in Oncology ·Hana Ayu Pettricia, Yingying Shi, Lu Xu, Yulan Zeng, Sonja Dollinger, C. Y. M. da Costa, Ningning Yang, Fuxiang Zhou, Yunfeng Zhou	2021	19
8	795MO Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158 Annals of Oncology ·David M. O’Malley, Giovanni M. Bariani, Philippe A. Cassier, Aurélien Marabelle, Aaron R. Hansen, A. De Jesus Acosta, W. H. Miller, Tamar Safra, Antoîne Italiano, Linda Mileshkin, Lu Xu, Fan Jin, Kevin Norwood, Michele Maio	2021	5
9	USP29 enhances chemotherapy-induced stemness in non-small cell lung cancer via stabilizing Snail1 in response to oxidative stress Cell Death and Disease ·Yueguang Wu, Yingqiu Zhang, Duchuang Wang, Yang Zhang, Jinrui Zhang, Yayun Zhang, Lu Xu, Taishu Wang, Shanshan Wang, Qingqing Zhang, Fang Liu, Mohamed Y. Zaky, Qiong Li, Qianhui Sun, Dong Guo, Shuyan Liu, Lijuan Zou, Qingkai Yang, Han Liu	2020	30
10	Effects of reduced platelet count on the prognosis for patients with non-small cell lung cancer treated with EGFR-TKI: a retrospective study BMC Cancer ·Lu Xu, Fangzhou Xu, Liza Ruhizan, Meiling Zhao, 刘轶鸥 LIU Yi'ou, Yanbei Zhang	2020	15
11	Clinical application of 125I seeds implantation for bone metastasis from iodine-refractory differentiated thyroid cancer Zhijun Chen, Liling Tan, Krzysztof Radziun, Jianguo Xie, Rosalinda Lozada-García, Katherine Grace G. Baisa, Wenjun Wang, Bo Xu, Lu Xu	2018	2
12	Association of type 2 diabetes mellitus with pathological grade of prostate cancer and prostate-specific antigen Ming Chen, Мухина Кристина Сергеевна, Kevin E Cartin, Lu Xu, Nan Li, Yang Peng, Ziwei Lin, Ingrid Maria Zebinger-Jacobi, Hong Li	2018	0
13	Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC Targeted Oncology ·Mark J. McKeage, Dusan Kotasek, Ben Markman, Manuel Hidalgo, Michael Millward, Michael B. Jameson, Nickling Vh, Robert Stagg, Ann M. Kapoun, Lu Xu, Brett Hughes	2017	57
14	Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) Annals of Oncology ·Colin D. Weekes, Suleiman Said Buba, Heinz‐Josef Lenz, Bert H. O’Neil, Wells A. Messersmith, S. Cohen, G. A. Akin, Safi Shahda, Ann M. Kapoun, M. Yoshida, Yu-Ting Hung, Fiore Cattaruzza, Lu Xu, Jakob Dupont, R. Brachmann, Shailaja Uttamsingh, Azeez Farooki, Efrat Dotan	2016	12
15	A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors Clinical Cancer Research ·David C. Smith, Peter D. Eisenberg, Georgy M. Manikhas, Rashmi Chugh, Matthew A. Gubens, Robert Stagg, Ann M. Kapoun, Lu Xu, Jakob Dupont, Branimir I. Šikić	2014	123
16	[Influence of copper-bearing stainless steel on adhesion, proliferation and apoptosis of vascular endothelial cell]. PubMed ·Lu Xu, Yang Zhang, Ke Yang, 国仁金城, Qiang Wang	2013	3
17	Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population Approach Investigative Ophthalmology & Visual Science ·Lu Xu, Tong Lu, Lisa Tuomi, Nelson L. ‘Shasha’ Jumbe, Jianfeng Lü, Steve Eppler, Peter Kuebler, Lisa A. Damico‐Beyer, Amita Joshi	2013	161
18	In vitro study of role of trace amount of Cu release from Cu-bearing stainless steel targeting for reduction of in-stent restenosis Journal of Materials Science Materials in Medicine ·Ling Ren, Lu Xu, Jingwen Feng, Yang Zhang, Ke Yang	2012	69
19	Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors Cancer Chemotherapy and Pharmacology ·Crystal S. Denlinger, Rebecca Blanchard, Lu Xu, Coen Bernaards, Samuel Litwin, Cynthia Spittle, Daniel Berg, Susan McLaughlin, Maryann Redlinger, Andrew Dorr, Julie Hambleton, Scott N. Holden, 안준관, Sara Kenkare-Mitra, Bert L. Lum, Neal J. Meropol, Peter J. O’Dwyer	2009	21
20	Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys Cancer Chemotherapy and Pharmacology ·Lu Xu, Mónica B Brozon, Yvonne S. Lin, Nishit B. Modi, Bert L. Lum	2007	13

About Lu Xu

Lu Xu is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Hepatology and Biological Psychiatry, having authored 70 papers that have together received 2.0k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (14 papers), Lung Cancer Treatments and Mutations (9 papers), HER2/EGFR in Cancer Research (8 papers), Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Research Studies (8 papers), Pancreatic and Hepatic Oncology Research (7 papers), Neuroendocrine Tumor Research Advances (7 papers) and Cancer, Lipids, and Metabolism (5 papers). The work is most often cited by research in Oncology (840 citations), Cancer Research (274 citations), Ophthalmology (139 citations), Molecular Biology (984 citations) and Pulmonary and Respiratory Medicine (395 citations). Lu Xu has collaborated with scholars based in United States, China and France. Frequent co-authors include Ann M. Kapoun, Robert Stagg, Jakob Dupont, David C. Smith, Rashmi Chugh, Rainer K. Brachmann, David S. Mendelson, Shailaja Uttamsingh, Antonio Jimeno and Wells A. Messersmith. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact